Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa

Goldberg, 2000, Pseudomonas: global bacteria, Trends Microbiol, 8, 55, 10.1016/S0966-842X(99)01671-6 Stover, 2000, Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen, Nature, 406, 959, 10.1038/35023079 Morrison, 1984, Epidemiology of infections due to Pseudomonas aeruginosa, Rev Infect Dis, 6, S627, 10.1093/clinids/6.Supplement_3.S627 Pollack, 2000, Pseudomonas aeruginosa, 2310 Anonymous, 1988, National Nosocomial Infections Surveillance (NNIS) System Report: data summary from October 1986 to April 1998, issued June 1998, Am J Infect Control, 26, 522 Vincent, 1995, The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee, J Am Med Assoc, 274, 639, 10.1001/jama.1995.03530080055041 Rajashekaraiah, 1981, Recovery of Pseudomonas aeruginosa from syringes of drug addicts with endocarditis, J Infect Dis, 144, 482, 10.1093/infdis/144.5.482 Fisher, 1985, Sneakers as a source of Pseudomonas aeruginosa in children with osteomyelitis following puncture wounds, J Pediatr, 106, 607, 10.1016/S0022-3476(85)80082-2 Rubin, 1988, Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy, Am J Med, 85, 391, 10.1016/0002-9343(88)90592-X Bottone, 1993, Pseudomonas aeruginosa folliculitis acquired through use of a contaminated loofah sponge: an unrecognized potential public health problem, J Clin Microbiol, 31, 480, 10.1128/JCM.31.3.480-483.1993 Holland, 1993, Pseudomonas aeruginosa ocular infections, 159 Komshian, 1990, Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center, Rev Infect Dis, 12, 693, 10.1093/clinids/12.4.693 Hatchette, 2000, Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature, Clin Infect Dis, 31, 1349, 10.1086/317486 Crouch Brewer, 1996, Ventilator-associated pneumonia due to Pseudomonas aeruginosa, Chest, 109, 1019, 10.1378/chest.109.4.1019 Mayhall, 1997, Nosocomial pneumonia. Diagnosis and prevention, Infect Dis Clin North Am, 11, 427, 10.1016/S0891-5520(05)70364-0 Rello, 1997, Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent, Crit Care Med, 25, 1862, 10.1097/00003246-199711000-00026 Anonymous, 1996, National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986 to April 1996, issued May 1996, Am J Infect Control, 24, 380, 10.1016/S0196-6553(96)90026-7 Bouza, 2002, Catheter-related infections: diagnosis and intravascular treatment, Clin Microbiol Infect, 8, 265, 10.1046/j.1469-0691.2002.00385.x Mousa, 1997, Aerobic, anaerobic and fungal burn wound infections, J Hosp Infect, 37, 317, 10.1016/S0195-6701(97)90148-1 Bodey, 1985, Pseudomonas bacteremia. Retrospective analysis of 410 episodes, Arch Intern Med, 145, 1621, 10.1001/archinte.1985.00360090089015 Gallagher, 1989, Pseudomonas bacteremia in a community teaching hospital 1980–1984, Rev Infect Dis, 11, 846, 10.1093/clinids/11.6.846 Siegman-Igra, 1998, Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy, Int J Infect Dis, 2, 211, 10.1016/S1201-9712(98)90055-8 Collin, 2001, Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients, Clin Infect Dis, 33, 947, 10.1086/322604 Koll, 1993, The changing epidemiology of infections at cancer hospitals, Clin Infect Dis, 17, S322, 10.1093/clinids/17.Supplement_2.S322 Aquino, 1995, The changing epidemiology of bacteremia in neutropenic children with cancer, Pediatr Infect Dis J, 14, 140, 10.1097/00006454-199502000-00011 Fishman, 1998, Infection in organ-transplant recipients, N Engl J Med, 338, 1741, 10.1056/NEJM199806113382407 Pizzo, 1999, Fever in immunocompromised patients, N Engl J Med, 341, 893, 10.1056/NEJM199909163411207 Maschmeyer, 2000, Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s, Eur J Clin Microbiol Infect Dis, 19, 915, 10.1007/s100960000410 Diekema, 1999, Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States. Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997, Clin Infect Dis, 29, 595, 10.1086/598640 Bernardini, 1987, Analysis of continuous ambulatory peritoneal dialysis-related Pseudomonas aeruginosa infections, Am J Med, 83, 829, 10.1016/0002-9343(87)90638-3 Davies, 2002, Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence, Paediatr Respir Rev, 3, 128, 10.1016/S1526-0550(02)00003-3 Dropulic, 1995, Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS, J Infect Dis, 171, 930, 10.1093/infdis/171.4.930 Vidal, 1999, Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1, Eur J Clin Microbiol Infect Dis, 18, 473, 10.1007/s100960050326 Manfredi, 2000, Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey, Eur J Epidemiol, 16, 111, 10.1023/A:1007626410724 Ramphal, 1985, Role of Pseudomonas aeruginosa mucoid exopolysaccharide in adherence to tracheal cells, Infect Immun, 47, 1, 10.1128/IAI.47.1.1-4.1985 Doig, 1988, Role of pili in adhesion of Pseudomonas aeruginosa to human respiratory epithelial cells, Infect Immun, 56, 1641, 10.1128/IAI.56.6.1641-1646.1988 Prince, 1992, Adhesins and receptors of Pseudomonas aeruginosa associated with infection of the respiratory tract, Microb Pathogen, 13, 251, 10.1016/0882-4010(92)90035-M Boyd, 1995, Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide, J Ind Microbiol, 15, 162, 10.1007/BF01569821 Hoiby, 2001, Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth, Microbes Infect, 3, 23, 10.1016/S1286-4579(00)01349-6 Drenkard, 2002, Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation, Nature, 416, 740, 10.1038/416740a Olson, 2002, Biofilm bacteria: formation and comparative susceptibility to antibiotics, Can J Vet Res, 66, 86 Berka, 1982, Phospholipase C (heat-labile hemolysin) of Pseudomonas aeruginosa: purification and preliminary characterization, J Bacteriol, 152, 239, 10.1128/jb.152.1.239-245.1982 Kharami, 1989, Effect of Pseudomonas aeruginosa rhamnolipid on human neutrophil and monocyte function, APMIS, 97, 1068, 10.1111/j.1699-0463.1989.tb00519.x Lutz, 1991, Pore-forming cytotoxin of Pseudomonas aeruginosa: the molecular effects and aspects of pathogenicity, Antibiot Chemother, 44, 54, 10.1159/000420297 Read, 1992, Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating, J Appl Physiol, 72, 2271, 10.1152/jappl.1992.72.6.2271 Komori, 2001, Hemorrhagic activity and muscle damaging effect of Pseudomonas aeruginosa metalloproteinase (elastase), Toxicon, 39, 1327, 10.1016/S0041-0101(01)00084-8 Pollack, 1980, Pseudomonas aeruginosa exotoxin A, N Engl J Med, 302, 1360, 10.1056/NEJM198006123022410 Pollack, 1983, The role of exotoxin A in Pseudomonas disease and immunity, Rev Infect Dis, 5, S979, 10.1093/clinids/5.Supplement_5.S979 Nicas, 1985, The role of exoenzyme S in infections with Pseudomonas aeruginosa, J Infect Dis, 152, 716, 10.1093/infdis/152.4.716 Hwang, 1987, Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli, Cell, 48, 129, 10.1016/0092-8674(87)90363-1 Coburn, 1992, Pseudomonas aeruginosa exoenzyme S, Curr Top Microbiol Immunol, 175, 133 Van Delden, 1998, Cell-to-cell signaling and Pseudomonas aeruginosa infections, Emerg Infect Dis, 4, 551, 10.3201/eid0404.980405 Rumbaugh, 2000, The role of quorum sensing in the in vivo virulence of Pseudomonas aeruginosa, Microbes Infect, 2, 1721, 10.1016/S1286-4579(00)01327-7 Winzer, 2001, Quorum sensing and the regulation of virulence gene expression in pathogenic bacteria, Int J Med Microbiol, 291, 131, 10.1078/1438-4221-00110 Smith, 2003, Pseudomonas aeruginosa quorum-sensing systems and virulence, Curr Opin Microbiol, 6, 56, 10.1016/S1369-5274(03)00008-0 Kiska, 2003, Pseudomonas, 719 Baselski, 1993, Microbiologic diagnosis of ventilator-associated pneumonia, Infect Dis Clin North Am, 7, 331, 10.1016/S0891-5520(20)30525-0 Livermore, 1995, β-Lactamases in laboratory and clinical resistance, Clin Microbiol Rev, 8, 557, 10.1128/CMR.8.4.557 Li, 2000, Interplay between the MexA–MexB–OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa, J Antimicrob Chemother, 45, 433, 10.1093/jac/45.4.433 Poole, 2001, Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms, J Mol Microbiol Biotechnol, 3, 255 Li, 1995, Role of mexA–mexB–oprM in antibiotic efflux in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 39, 1948, 10.1128/AAC.39.9.1948 Kohler, 1997, Characterization of MexE–MexF–OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa, Mol Microbiol, 23, 345, 10.1046/j.1365-2958.1997.2281594.x Masuda, 2000, Contribution of the MexX–MexY–oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 44, 2242, 10.1128/AAC.44.9.2242-2246.2000 Masuda, 2000, Substrate specificities of MexAB–OprM, MexCD–OprJ, and MexXY–oprM efflux pumps in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 44, 3322, 10.1128/AAC.44.12.3322-3327.2000 Jo, 2003, Aminoglycoside efflux in Pseudomonas aeruginosa. Involvement of novel outer membrane proteins, Antimicrob Agents Chemother, 47, 1101, 10.1128/AAC.47.3.1101-1111.2003 Giamarellou, 2001, Antipseudomonal antibiotics, Med Clin North Am, 85, 19, 10.1016/S0025-7125(05)70303-5 Jones, 2001, Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!, Diagn Microbiol Infect Dis, 41, 161, 10.1016/S0732-8893(01)00287-5 Giamarellou, 2002, Prescribing guidelines for severe Pseudomonas infections, J Antimicrob Chemother, 49, 229, 10.1093/jac/49.2.229 Lister, 1999, Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin, Antimicrob Agents Chemother, 43, 882, 10.1128/AAC.43.4.882 Lister, 2000, β-Lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against Enterobacteriaceae and Pseudomonas aeruginosa, Pharmacotherapy, 20, S213, 10.1592/phco.20.14.213S.35045 Sanders, 1992, β-Lactam resistance in gram-negative bacteria: global trends and clinical impact, Clin Infect Dis, 15, 824, 10.1093/clind/15.5.824 Campbell, 1997, Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different β-lactamase expression phenotypes but are homogeneous in the ampC–ampR genetic region, Antimicrob Agents Chemother, 41, 1380, 10.1128/AAC.41.6.1380 Langaee, 2000, Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC β-lactamase expression, Antimicrob Agents Chemother, 44, 583, 10.1128/AAC.44.3.583-589.2000 Bagge, 2002, Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD, Antimicrob Agents Chemother, 46, 3406, 10.1128/AAC.46.11.3406-3411.2002 Livermore, 2001, Of Pseudomonas, porins, pumps and carbapenems, J Antimicrob Chemother, 47, 247, 10.1093/jac/47.3.247 Köhler, 2001, In vitro selection of antibiotic resistance in Pseudomonas aeruginosa, Clin Microbiol Infect, 7, 7, 10.1046/j.1469-0691.2001.00066.x Yoneyama, 1993, Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa, Antimicrob Agents Chemother, 37, 2385, 10.1128/AAC.37.11.2385 Pirnay, 2002, Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates, Environ Microbiol, 4, 872, 10.1046/j.1462-2920.2002.00281.x Köhler, 1999, Characterization of MexT, the regulator of the MexE–MexF–OprN multidrug efflux system of Pseudomonas aeruginosa, J Bacteriol, 181, 6300, 10.1128/JB.181.20.6300-6305.1999 Ziha-Zarifi, 1999, In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA–MexB–OprM, Antimicrob Agents Chemother, 43, 287, 10.1128/AAC.43.2.287 Saito, 1999, nalB-type mutations causing the overexpression of the MexAB–OprM efflux pump are located in the mexR gene of the Pseudomonas aeruginosa chromosome, FEMS Microbiol Lett, 179, 67, 10.1111/j.1574-6968.1999.tb08709.x Srikumar, 2000, Influence of mutations in the mexR repressor gene on expression of the MexA–MexB–oprM multidrug efflux system of Pseudomonas aeruginosa, J Bacteriol, 182, 1410, 10.1128/JB.182.5.1410-1414.2000 Bush, 1995, A functional classification scheme for β-lactamases and its correlation with molecular structure, Antimicrob Agents Chemother, 39, 1211, 10.1128/AAC.39.6.1211 Naas, 1999, OXA-type β-lactamases, Curr Pharm Des, 5, 865, 10.2174/1381612805666230112185101 Bradford, 2001, Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance treat, Clin Microbiol Rev, 14, 933, 10.1128/CMR.14.4.933-951.2001 Mavroidi, 2001, An integron-associated β-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum β-lactamase IBC-1, J Antimicrob Chemother, 48, 627, 10.1093/jac/48.5.627 Dubois, 2002, Molecular characterization of a novel class 1 integron containing blaGES-1 and a fused product of aac3-Ib/aac6'-Ib’ gene cassettes in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 46, 638, 10.1128/AAC.46.3.638-645.2002 Poirel, 2001, GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem, Antimicrob Agents Chemother, 45, 2598, 10.1128/AAC.45.9.2598-2603.2001 Bush, 1998, Metallo-β-lactamases: a class apart, Clin Infect Dis, 27, S48, 10.1086/514922 Nordmann, 2002, Emerging carbapenemases in Gram-negative aerobes, Clin Microbiol Infect, 8, 321, 10.1046/j.1469-0691.2002.00401.x Toleman, 2002, Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme, J Antimicrob Chemother, 50, 673, 10.1093/jac/dkf210 Docquier, 2003, Diversity of IMP-type metallo-β-lactamases in carbapenem resistant clinical isolates of Pseudomonas spp. from Italy, 583 Castanheira, 2004, Molecular characterization of a β-lactamase gene, blaGIM-1, encoding a new subclass of metallo-β-lactamase, Antimicrob Agents Chemother, 48, 4654, 10.1128/AAC.48.12.4654-4661.2004 Bush, 1999, β-Lactamases of increasing clinical importance, Curr Pharm Des, 5, 839, 10.2174/1381612805666230112183102 Livermore, 2000, Carbapenemases: a problem in waiting?, Curr Opin Microbiol, 3, 489, 10.1016/S1369-5274(00)00128-4 Bush, 2001, New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy, Clin Infect Dis, 32, 1085, 10.1086/319610 Docquier, 2001, Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine-β-lactamase and VIM-2 metallo-β-lactamase, Emerg Infect Dis, 7, 910, 10.3201/eid0705.010528 Hancock, 1998, Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria, Clin Infect Dis, 27, S93, 10.1086/514909 Shaw, 1993, Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes, Microbiol Rev, 57, 138, 10.1128/MMBR.57.1.138-163.1993 Miller, 1997, The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups, Clin Infect Dis, 24, S46, 10.1093/clinids/24.Supplement_1.S46 Bryan, 1984, Lipopolysaccharide changes in impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 26, 250, 10.1128/AAC.26.2.250 Nakano, 1997, Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 41, 2289, 10.1128/AAC.41.10.2289 Akasaka, 2001, Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance, Antimicrob Agents Chemother, 45, 2263, 10.1128/AAC.45.8.2263-2268.2001 Piddock, 1999, Mechanisms of fluoroquinolone resistance: an update 1994–1998, Drugs, 58, 11, 10.2165/00003495-199958002-00003 Le Thomas, 2001, In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy, J Antimicrob Chemother, 48, 553, 10.1093/jac/48.4.553 Livermore, 2002, Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?, Clin Infect Dis, 34, 634, 10.1086/338782 Livermore, 1992, Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa, Antimicrob Agents Chemother, 36, 2046, 10.1128/AAC.36.9.2046 Carmeli, 1999, Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents, Antimicrob Agents Chemother, 43, 1379, 10.1128/AAC.43.6.1379 Calandra, 1986, Cross-resistance and imipenem, Lancet, 2, 340, 10.1016/S0140-6736(86)90027-9 Norrby, 1993, Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group, J Antimicrob Chemother, 31, 927, 10.1093/jac/31.6.927 Fink, 1994, Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group, Antimicrob Agents Chemother, 38, 547, 10.1128/AAC.38.3.547 Jaccard, 1998, Prospective randomized comparison of imipenem–cilastatin and piperacillin–tazobactam in nosocomial pneumonia or peritonitis, Antimicrob Agents Chemother, 42, 2966, 10.1128/AAC.42.11.2966 Laraki, 1999, Structure of In31, a blaIMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes, Antimicrob Agents Chemother, 43, 890, 10.1128/AAC.43.4.890 Pallecchi, 2001, Molecular heterogeneity of blaVIM-2-containing integrons from Pseudomonas aeruginosa plasmids encoding Rossolini and Mantengoli Multiresistant Pseudomonas aeruginosa the VIM-2 metallo-β-lactamase, FEMS Microbiol Lett, 195, 145 Poirel, 2001, Characterization of Class 1 integrons from Pseudomonas aeruginosa that contain the blaVIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes, Antimicrob Agents Chemother, 45, 546, 10.1128/AAC.45.2.546-552.2001 Poirel, 2001, OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene, Antimicrob Agents Chemother, 45, 447, 10.1128/AAC.45.2.447-453.2001 Fridkin, 1999, Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals, Clin Infect Dis, 29, 245, 10.1086/520193 Bonfiglio, 1998, Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey, J Antimicrob Chemother, 41, 307, 10.1093/jac/41.2.307 Bouza, 1999, Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group, Antimicrob Agents Chemother, 43, 981, 10.1128/AAC.43.4.981 Henwood, 2001, Pseudomonas Study Group. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test, J Antimicrob Chemother, 47, 789, 10.1093/jac/47.6.789 Van Eldere, 2003, Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections, J Antimicrob Chemother, 51, 347, 10.1093/jac/dkg102 Friedland, 2003, Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995–2000, Diagn Microbiol Infect Dis, 45, 245, 10.1016/S0732-8893(02)00503-5 Karlowsky, 2003, Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998–2001, Antimicrob Agents Chemother, 47, 1681, 10.1128/AAC.47.5.1681-1688.2003 Ibrahim, 2000, The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting, Chest, 118, 146, 10.1378/chest.118.1.146 Jones, 2002, Geographic variations in activity of broad spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY antimicrobial surveillance program (1997–2000), Diagn Microbiol Infect Dis, 43, 239, 10.1016/S0732-8893(02)00390-5 Fluit, 2000, Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY participants, Eur J Clin Microbiol Infect Dis, 19, 370, 10.1007/s100960050497 Mendes, 2001, Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997–2000), Diagn Microbiol Infect Dis, 41, 191, 10.1016/S0732-8893(01)00321-2 Hanberger, 2001, Surveillance of antibiotic resistance in European ICUs, J Hosp Infect, 48, 161, 10.1053/jhin.2001.0987 Pfaller, 2001, Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA), Diagn Microbiol Infect Dis, 41, 177, 10.1016/S0732-8893(01)00319-4 Gales, 2001, Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program 1997–1999, Clin Infect Dis, 32, S146, 10.1086/320186 Rossolini, 2000, Carbapenem-resistant Pseudomonas aeruginosa with acquired blaVIM metallo-β-lactamase determinants, Italy, Emerg Infect Dis, 6, 312, 10.3201/eid0603.000314 Cornaglia, 2000, Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase, Clin Infect Dis, 31, 1119, 10.1086/317448 Pournaras, 2003, Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-β-lactamase gene variants blaVIM-2 and blaVIM-4, J Antimicrob Chemother, 51, 1409, 10.1093/jac/dkg239 Sardelic, 2003, Carbapenem-resistant Pseudomonas aeruginosa-carrying VIM-2 metallo-β-lactamase determinants, Croatia, Emerg Infect Dis, 9, 1022, 10.3201/eid0908.020373 Levin, 1999, Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, Clin Infect Dis, 28, 1008, 10.1086/514732 Evans, 1999, Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria, Ann Pharmacother, 33, 960, 10.1345/aph.18426 Luzzaro, 2001, Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase, J Clin Microbiol, 39, 1865, 10.1128/JCM.39.5.1865-1870.2001 Gales, 2001, Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines, J Clin Microbiol, 39, 183, 10.1128/JCM.39.1.183-190.2001 Giamarellou, 1984, In vitro synergistic activities of aminoglycosides and new β-lactams against multiresistant Pseudomonas aeruginosa, Antimicrob Agents Chemother, 25, 534, 10.1128/AAC.25.4.534 Giamarellos-Bourboulis, 1996, In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa, J Antimicrob Chemother, 38, 287, 10.1093/jac/38.2.287 Burgess, 2000, Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin and trovafloxacin against Pseudomonas aeruginosa by time-kill, Diagn Microbiol Infect Dis, 38, 37, 10.1016/S0732-8893(00)00162-0 Anonymous, 1987, Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group, N Engl J Med, 317, 1692, 10.1056/NEJM198712313172703 Hilf, 1989, Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients, Am J Med, 87, 540, 10.1016/S0002-9343(89)80611-4 Leibovici, 1997, Monotherapy versus β-lactam–aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study, Antimicrob Agents Chemother, 41, 1127, 10.1128/AAC.41.5.1127 Fainstein, 1983, A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients, J Antimicrob Chemother, 12, 101, 10.1093/jac/12.suppl_A.101 Vidal, 1996, Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes, Arch Intern Med, 156, 2121, 10.1001/archinte.1996.00440170139015 Chow, 1999, Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary, Int J Antimicrob Agents, 11, 7, 10.1016/S0924-8579(98)00060-0 Anderson, 1978, Antimicrobial synergism in the therapy of gram-negative rod bacteremia, Chemotherapy, 24, 45, 10.1159/000237759 De Jongh, 1986, Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients, Am J Med, 80, 96 Klastersky, 1998, Science and pragmatism in the treatment and prevention of neutropenic infection, J Antimicrob Chemother, 41, 13, 10.1093/jac/41.suppl_4.13 Pizzo, 1986, A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia, N Engl J Med, 315, 552, 10.1056/NEJM198608283150905 Cometta, 1996, Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer, Antimicrob Agents Chemother, 40, 1108, 10.1128/AAC.40.5.1108 Ramphal, 1996, Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient, Am J Med, 100, S83, 10.1016/S0002-9343(96)00113-1 Hess, 1998, Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients, Support Care Cancer, 6, 402, 10.1007/s005200050184 Del Favero, 2001, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. A multicenter, double-blind, placebo-controlled trial comparing piperacillin–tazobactam with and without amikacin as empiric therapy for febrile neutropenia, Clin Infect Dis, 33, 1295, 10.1086/322646 Furno, 2002, Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis, Lancet Infect Dis, 2, 231, 10.1016/S1473-3099(02)00241-4 Viscoli, 2002, Treatment of febrile neutropenia: what is new?, Curr Opin Infect Dis, 15, 377, 10.1097/00001432-200208000-00004 Doring, 2000, Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus, Eur Respir J, 16, 749, 10.1034/j.1399-3003.2000.16d30.x Ratjen, 2001, Changes in strategies for optimal antibacterial therapy in cystic fibrosis, Int J Antimicrob Agents, 17, 93, 10.1016/S0924-8579(00)00333-2 Hoiby, 2002, New antimicrobials in the management of cystic fibrosis, J Antimicrob Chemother, 49, 235, 10.1093/jac/49.2.235 Rahal, 1998, Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella, J Am Med Assoc, 280, 1233, 10.1001/jama.280.14.1233 Lepper, 2002, Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 46, 2920, 10.1128/AAC.46.9.2920-2925.2002 Trouillet, 2002, Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms, Clin Infect Dis, 34, 1047, 10.1086/339488 Harris, 2002, Risk factors for imipenem-resistant Pseudomonas aeruginosa among hopitalized patients, Clin Infect Dis, 34, 340, 10.1086/338237 Harris, 2002, Risk factors for piperacillin–tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients, Antimicrob Agents Chemother, 46, 854, 10.1128/AAC.46.3.854-858.2002 Regal, 2003, The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to β-lactams in a large teaching hospital, Pharmacotherapy, 23, 618, 10.1592/phco.23.5.618.32197 Gruson, 2000, Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria, Am J Respir Crit Care Med, 162, 837, 10.1164/ajrccm.162.3.9905050 Rice, 1996, Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center, Clin Infect Dis, 23, 118, 10.1093/clinids/23.1.118 Rice, 1999, Successful interventions for gram-negative resistance to extended-spectrum β-lactam antiobiotics, Pharmacotherapy, 19, S120, 10.1592/phco.19.12.120S.31699 Widmer, 1993, Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: probable transmission via hands of a health care worker, Clin Infect Dis, 16, 372, 10.1093/clind/16.3.372 Moolenaar, 2000, A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission?, Infect Control Hosp Epidemiol, 21, 80, 10.1086/501739 Piddock, 1998, Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract, Antimicrob Agents Chemother, 42, 2956, 10.1128/AAC.42.11.2956 Lomovskaya, 2001, Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria, J Mol Microbiol Biotechnol, 3, 225 Miller, 2001, β-lactamase-inhibitor combinations in the 21st century: current agents and new developments, Curr Opin Pharmacol, 1, 451, 10.1016/S1471-4892(01)00079-0 Toney, 2003, Metallo-β-lactamase inhibitors: could they give old antibacterials new life?, Curr Opin Invest Drugs, 4, 115 Chopra, 1998, Research and development of antibacterial agents, Curr Opin Microbiol, 1, 495, 10.1016/S1369-5274(98)80080-5 Hancock, 2000, Cationic antimicrobial peptides: towards clinical applications, Expert Opin Invest Drugs, 9, 1723, 10.1517/13543784.9.8.1723 Yau, 2001, High therapeutic index of factor C Sushi peptides: potent antimicrobials against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 45, 2820, 10.1128/AAC.45.10.2820-2825.2001